
Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.

Eli Lilly continues to emphasize the potential harm that could come with using GLP-1 receptor agonists for off-label purposes.

Chases discusses how traditional media platforms still coexist with digital platforms and how this impacts promotion.

The partnership has the goal of improving patient education and treatment directions.

Rebranding aims to align company with its parent company and other subsidiaries.

Commentary cites lower control over health plan costs and the potential bias for prescribing drugs through influence from drug manufacturers.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z

Letter emphasizes the need to protect children from potentially harmful medical advice spread on social media.

Researchers highlight several benefits and concerns associated with the launch of direct-to-consumer models for GLP-1 receptor agonists.

The campaign, that started in 2012, is back with seven new faces—many of which included messaging about the harms of menthol cigarettes.

Treatment aims to reduce the risk of finger or toe amputation due to frostbite.

Webcasts
Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT

According to the study conducted by Technavio, North America will contribute to 37% of the expected growth.

Joint venture aims to submit an Investigational New Drug application to the FDA by early next year for treatment that targets solid tumors.

The company has struggled to supply the drug to patients due to overwhelming popularity.

Rusfertide is currently in a pivotal Phase III clinical trial as a potential first-in-class treatment for polycythemia vera.

Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency's Peripheral and Central Nervous System Drugs Advisory Committee.

The shake is designed to work with regular dieters and those taking weight loss medications.

Eli Lilly advertisement emphasizes that advancements in in medicine can lead to improved population health.

Learnings from a roundtable discussion with Medical Affairs leadership from 11 pharma companies

Webcasts
Webinar Date/Time: Wednesday, March 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Data utilization in real-time targeting is a linchpin for success in navigating the intricacies of contemporary pharmaceutical marketing dynamics.

Pharma marketing strategies that are both socially and ethically responsible can build long term success for the life sciences industry.

With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.

The biosimilar Cimerli carries the interchangeability designation for the treatment of wet age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, and diabetic retinopathy.